NATURE . COM {}

Matching Content Categories {📚}

• Education
• Health & Fitness
• Science

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}

Display Ads {🎯}

The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)

google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)

conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}

Display Ads {🎯}

$63,100 per month
Our analysis indicates Nature.com generates between $42,042 and $115,616 monthly online from display ads.

Keywords {🔍}

cancer, google, scholar, article, activity, drug, nature, vivo, models, hollow, fibre, tumor, cas, preclinical, development, vitro, compounds, content, tested, human, cell, anticancer, cookies, journal, open, clinical, trials, xenograft, screening, practice, oncology, privacy, data, access, national, agents, correlation, assay, intraperitoneal, response, research, devita, hellmann, rosenberg, principles, lippincottraven, philadelphia, analysis, british, nci,

Topics {✒️}

nature portfolio medicinal chemistry libraries nature privacy policy advertising social media 0/ reprints anticancer drug development pharmaceutical policy permissions personal data xenograft data preclinical drug development hollow fiber assay animal models utilized phase ii trials data protection cancer drug discovery cancer chemotherapeutic agents vitro antitumor screen privacy developmental therapeutics program hollow fibre responses molecular docking studies hollow fibre assay hollow fibre activity journals search log explore content early clinical trials tumor panel screening subcutaneous activity combined tumor development national cancer institute' human cancer histology national cancer institute anti-cancer effect european economic area 4h-chromen-7-yl ]quinoline-based heterocycles knowledge-based approach americal chemical society ox40 agonist alexander accepting optional cookies microculture tetrazolium assay anti-proliferative activity finding xenograft activity vivo tumour models hydrogen-bonding factors pre-clinical models antitumor drugs

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
         description:An analysis of the activity of compounds tested in pre-clinical in vivo and in vitro assays by the National Cancer Institute's Developmental Therapeutics Program was performed. For 39 agents with both xenograft data and Phase II clinical trials results available, in vivo activity in a particular histology in a tumour model did not closely correlate with activity in the same human cancer histology, casting doubt on the correspondence of the pre-clinical models to clinical results. However, for compounds with in vivo activity in at least one-third of tested xenograft models, there was correlation with ultimate activity in at least some Phase II trials. Thus, an efficient means of predicting activity in vivo models remains desirable for compounds with anti-proliferative activity in vitro. For 564 compounds tested in the hollow fibre assay which were also tested against in vivo tumour models, the likelihood of finding xenograft activity in at least one-third of the in vivo models tested rose with increasing intraperitoneal hollow fibre activity, from 8% for all compounds tested to 20% in agents with evidence of response in more than 6 intraperitoneal fibres (P< 0.0001). Intraperitoneal hollow fibre activity was also found to be a better predictor of xenograft activity than either subcutaneous hollow fibre activity or intraperitoneal plus subcutaneous activity combined. Since hollow fibre activity was a useful indicator of potential in vivo response, correlates with hollow fibre activity were examined for 2304 compounds tested in both the NCI 60 cell line in vitro cancer drug screen and hollow fibre assay. A positive correlation was found for histologic selectivity between in vitro and hollow fibre responses. The most striking correlation was between potency in the 60 cell line screen and hollow fibre activity; 56% of compounds with mean 50% growth inhibition below 10–7.5 M were active in more than 6 intraperitoneal fibres whereas only 4% of compounds with a potency of 10–4 M achieved the same level of hollow fibre activity (P< 0.0001). Structural parameters of the drugs analysed included compound molecular weight and hydrogen-bonding factors, both of which were found to be predictive of hollow fibre activity. © 2001 Cancer Research Campaign
         datePublished:2001-05-15T00:00:00Z
         dateModified:2011-11-16T00:00:00Z
         pageStart:1424
         pageEnd:1431
         sameAs:https://doi.org/10.1054/bjoc.2001.1796
         keywords:
            anticancer drug discovery
            in vitro-to-in vivo correlations
            clinical trials
            Biomedicine
            general
            Cancer Research
            Epidemiology
            Molecular Medicine
            Oncology
            Drug Resistance
         image:
         isPartOf:
            name:British Journal of Cancer
            issn:
               1532-1827
               0007-0920
            volumeNumber:84
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:J I Johnson
               affiliation:
                     name:Developmental Therapeutics Program
                     address:
                        name:Developmental Therapeutics Program, Bethesda
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S Decker
               affiliation:
                     name:Developmental Therapeutics Program
                     address:
                        name:Developmental Therapeutics Program, Bethesda
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D Zaharevitz
               affiliation:
                     name:Developmental Therapeutics Program
                     address:
                        name:Developmental Therapeutics Program, Bethesda
                        type:PostalAddress
                     type:Organization
               type:Person
               name:L V Rubinstein
               affiliation:
                     name:Cancer Therapy Evaluation Program, National Cancer Institute
                     address:
                        name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J M Venditti
               affiliation:
                     name:SAIC-Frederick
                     address:
                        name:SAIC-Frederick, Frederick
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S Schepartz
               affiliation:
                     name:SAIC-Frederick
                     address:
                        name:SAIC-Frederick, Frederick
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S Kalyandrug
               affiliation:
                     name:Cancer Therapy Evaluation Program, National Cancer Institute
                     address:
                        name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M Christian
               affiliation:
                     name:Cancer Therapy Evaluation Program, National Cancer Institute
                     address:
                        name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S Arbuck
               affiliation:
                     name:Cancer Therapy Evaluation Program, National Cancer Institute
                     address:
                        name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M Hollingshead
               affiliation:
                     name:Developmental Therapeutics Program
                     address:
                        name:Developmental Therapeutics Program, Bethesda
                        type:PostalAddress
                     type:Organization
               type:Person
               name:E A Sausville
               affiliation:
                     name:Developmental Therapeutics Program
                     address:
                        name:Developmental Therapeutics Program, Bethesda
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
      description:An analysis of the activity of compounds tested in pre-clinical in vivo and in vitro assays by the National Cancer Institute's Developmental Therapeutics Program was performed. For 39 agents with both xenograft data and Phase II clinical trials results available, in vivo activity in a particular histology in a tumour model did not closely correlate with activity in the same human cancer histology, casting doubt on the correspondence of the pre-clinical models to clinical results. However, for compounds with in vivo activity in at least one-third of tested xenograft models, there was correlation with ultimate activity in at least some Phase II trials. Thus, an efficient means of predicting activity in vivo models remains desirable for compounds with anti-proliferative activity in vitro. For 564 compounds tested in the hollow fibre assay which were also tested against in vivo tumour models, the likelihood of finding xenograft activity in at least one-third of the in vivo models tested rose with increasing intraperitoneal hollow fibre activity, from 8% for all compounds tested to 20% in agents with evidence of response in more than 6 intraperitoneal fibres (P< 0.0001). Intraperitoneal hollow fibre activity was also found to be a better predictor of xenograft activity than either subcutaneous hollow fibre activity or intraperitoneal plus subcutaneous activity combined. Since hollow fibre activity was a useful indicator of potential in vivo response, correlates with hollow fibre activity were examined for 2304 compounds tested in both the NCI 60 cell line in vitro cancer drug screen and hollow fibre assay. A positive correlation was found for histologic selectivity between in vitro and hollow fibre responses. The most striking correlation was between potency in the 60 cell line screen and hollow fibre activity; 56% of compounds with mean 50% growth inhibition below 10–7.5 M were active in more than 6 intraperitoneal fibres whereas only 4% of compounds with a potency of 10–4 M achieved the same level of hollow fibre activity (P< 0.0001). Structural parameters of the drugs analysed included compound molecular weight and hydrogen-bonding factors, both of which were found to be predictive of hollow fibre activity. © 2001 Cancer Research Campaign
      datePublished:2001-05-15T00:00:00Z
      dateModified:2011-11-16T00:00:00Z
      pageStart:1424
      pageEnd:1431
      sameAs:https://doi.org/10.1054/bjoc.2001.1796
      keywords:
         anticancer drug discovery
         in vitro-to-in vivo correlations
         clinical trials
         Biomedicine
         general
         Cancer Research
         Epidemiology
         Molecular Medicine
         Oncology
         Drug Resistance
      image:
      isPartOf:
         name:British Journal of Cancer
         issn:
            1532-1827
            0007-0920
         volumeNumber:84
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:J I Johnson
            affiliation:
                  name:Developmental Therapeutics Program
                  address:
                     name:Developmental Therapeutics Program, Bethesda
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S Decker
            affiliation:
                  name:Developmental Therapeutics Program
                  address:
                     name:Developmental Therapeutics Program, Bethesda
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D Zaharevitz
            affiliation:
                  name:Developmental Therapeutics Program
                  address:
                     name:Developmental Therapeutics Program, Bethesda
                     type:PostalAddress
                  type:Organization
            type:Person
            name:L V Rubinstein
            affiliation:
                  name:Cancer Therapy Evaluation Program, National Cancer Institute
                  address:
                     name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J M Venditti
            affiliation:
                  name:SAIC-Frederick
                  address:
                     name:SAIC-Frederick, Frederick
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S Schepartz
            affiliation:
                  name:SAIC-Frederick
                  address:
                     name:SAIC-Frederick, Frederick
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S Kalyandrug
            affiliation:
                  name:Cancer Therapy Evaluation Program, National Cancer Institute
                  address:
                     name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M Christian
            affiliation:
                  name:Cancer Therapy Evaluation Program, National Cancer Institute
                  address:
                     name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S Arbuck
            affiliation:
                  name:Cancer Therapy Evaluation Program, National Cancer Institute
                  address:
                     name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M Hollingshead
            affiliation:
                  name:Developmental Therapeutics Program
                  address:
                     name:Developmental Therapeutics Program, Bethesda
                     type:PostalAddress
                  type:Organization
            type:Person
            name:E A Sausville
            affiliation:
                  name:Developmental Therapeutics Program
                  address:
                     name:Developmental Therapeutics Program, Bethesda
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:British Journal of Cancer
      issn:
         1532-1827
         0007-0920
      volumeNumber:84
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Developmental Therapeutics Program
      address:
         name:Developmental Therapeutics Program, Bethesda
         type:PostalAddress
      name:Developmental Therapeutics Program
      address:
         name:Developmental Therapeutics Program, Bethesda
         type:PostalAddress
      name:Developmental Therapeutics Program
      address:
         name:Developmental Therapeutics Program, Bethesda
         type:PostalAddress
      name:Cancer Therapy Evaluation Program, National Cancer Institute
      address:
         name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
         type:PostalAddress
      name:SAIC-Frederick
      address:
         name:SAIC-Frederick, Frederick
         type:PostalAddress
      name:SAIC-Frederick
      address:
         name:SAIC-Frederick, Frederick
         type:PostalAddress
      name:Cancer Therapy Evaluation Program, National Cancer Institute
      address:
         name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
         type:PostalAddress
      name:Cancer Therapy Evaluation Program, National Cancer Institute
      address:
         name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
         type:PostalAddress
      name:Cancer Therapy Evaluation Program, National Cancer Institute
      address:
         name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
         type:PostalAddress
      name:Developmental Therapeutics Program
      address:
         name:Developmental Therapeutics Program, Bethesda
         type:PostalAddress
      name:Developmental Therapeutics Program
      address:
         name:Developmental Therapeutics Program, Bethesda
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:J I Johnson
      affiliation:
            name:Developmental Therapeutics Program
            address:
               name:Developmental Therapeutics Program, Bethesda
               type:PostalAddress
            type:Organization
      name:S Decker
      affiliation:
            name:Developmental Therapeutics Program
            address:
               name:Developmental Therapeutics Program, Bethesda
               type:PostalAddress
            type:Organization
      name:D Zaharevitz
      affiliation:
            name:Developmental Therapeutics Program
            address:
               name:Developmental Therapeutics Program, Bethesda
               type:PostalAddress
            type:Organization
      name:L V Rubinstein
      affiliation:
            name:Cancer Therapy Evaluation Program, National Cancer Institute
            address:
               name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
               type:PostalAddress
            type:Organization
      name:J M Venditti
      affiliation:
            name:SAIC-Frederick
            address:
               name:SAIC-Frederick, Frederick
               type:PostalAddress
            type:Organization
      name:S Schepartz
      affiliation:
            name:SAIC-Frederick
            address:
               name:SAIC-Frederick, Frederick
               type:PostalAddress
            type:Organization
      name:S Kalyandrug
      affiliation:
            name:Cancer Therapy Evaluation Program, National Cancer Institute
            address:
               name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
               type:PostalAddress
            type:Organization
      name:M Christian
      affiliation:
            name:Cancer Therapy Evaluation Program, National Cancer Institute
            address:
               name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
               type:PostalAddress
            type:Organization
      name:S Arbuck
      affiliation:
            name:Cancer Therapy Evaluation Program, National Cancer Institute
            address:
               name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
               type:PostalAddress
            type:Organization
      name:M Hollingshead
      affiliation:
            name:Developmental Therapeutics Program
            address:
               name:Developmental Therapeutics Program, Bethesda
               type:PostalAddress
            type:Organization
      name:E A Sausville
      affiliation:
            name:Developmental Therapeutics Program
            address:
               name:Developmental Therapeutics Program, Bethesda
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Developmental Therapeutics Program, Bethesda
      name:Developmental Therapeutics Program, Bethesda
      name:Developmental Therapeutics Program, Bethesda
      name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
      name:SAIC-Frederick, Frederick
      name:SAIC-Frederick, Frederick
      name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
      name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
      name:Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda
      name:Developmental Therapeutics Program, Bethesda
      name:Developmental Therapeutics Program, Bethesda

Social Networks {👍}(1)

• https://twitter.com/BrJCancer

External Links {🔗}(68)

• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=3335022's total income per month
• How much money does http://scholar.google.com/scholar_lookup?&title=Feasibility%20of%20drug%20screening%20with%20panels%20of%20human%20tumor%20cell%20lines%20using%20a%20microculture%20tetrazolium%20assay&journal=Cancer%20Res&volume=48&pages=589-601&publication_year=1988&author=Alley%2CMC&author=Scudiero%2CDA&author=Monks%2CA&author=Hursey%2CML&author=Czerwinski%2CMJ&author=Fine%2CDL&author=Abbott%2CBJ&author=Mayo%2CJG&author=Shoemaker%2CRH&author=Boyd%2CMR make?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Cancer%20Principles%20and%20Practice%20of%20Oncology&publication_year=1982&author=DeVita%2CVT&author=Hellmann%2CS&author=Rosenberg%2CSA make?
• How much income is http://scholar.google.com/scholar_lookup?&title=Cancer%20Principles%20and%20Practice%20of%20Oncology&publication_year=1985&author=DeVita%2CVT&author=Hellmann%2CS&author=Rosenberg%2CSA earning monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=Cancer%20Principles%20and%20Practice%20of%20Oncology&publication_year=1989&author=DeVita%2CVT&author=Hellmann%2CS&author=Rosenberg%2CSA gross monthly?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Cancer%20Principles%20and%20Practice%20of%20Oncology&publication_year=1993&author=DeVita%2CVT&author=Hellmann%2CS&author=Rosenberg%2CSA make?
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Cancer%20Principles%20and%20Practice%20of%20Oncology&publication_year=1997&author=DeVita%2CVT&author=Hellmann%2CS&author=Rosenberg%2CSA
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Development%20of%20human%20tumor%20xenograft%20models%20for%20in%20vivo%20evaluation%20of%20new%20antitumor%20drugs&journal=Contrib%20Oncol&volume=42&pages=1-22&publication_year=1992&author=Dykes%2CDJ&author=Abbott%2CBJ&author=Mayo%2CJG&author=Harrison%2CSD&author=Laster%2CWR&author=Simpson-Herren%2CL&author=Griswold%2CDP
• https://doi.org/10.1016%2FS0065-230X%2808%2960917-3's financial summary
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Investigation%20of%20diverse%20systems%20for%20cancer%20chemotherapy%20screening&journal=Cancer%20Res%20Suppl&doi=10.1016%2FS0065-230X%2808%2960917-3&volume=3&pages=1-125&publication_year=1955&author=Gellhorn%2CA&author=Hirschberg%2CE?
• How much revenue does https://doi.org/10.1021%2Fcc9800071 generate?
• How much does http://scholar.google.com/scholar_lookup?&title=A%20knowledge-based%20approach%20in%20designing%20combinatorial%20or%20medicinal%20chemistry%20libraries%20for%20drug%20discovery.%201.%20A%20qualitative%20and%20quantitative%20characterization%20of%20known%20drug%20databases&journal=J%20Comb%20Chem&doi=10.1021%2Fcc9800071&volume=1&pages=55-68&publication_year=1999&author=Ghose%2CAK&author=Viswanadhan%2CVN&author=Wendoloski%2CJJ gross monthly?
• How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10519381 make?
• What are the earnings of http://scholar.google.com/scholar_lookup?&title=Tumor%20development%20under%20angiogenic%20signaling%3A%20a%20dynamical%20theory%20of%20tumor%20growth%2C%20treatment%20response%2C%20and%20postvasular%20dormancy&journal=Cancer%20Res&volume=59&pages=4770-4775&publication_year=1999&author=Hahnfeldt%2CP&author=Panigrahy%2CD&author=Folkman%2CJ&author=Hlatky%2CL?
• How much income does http://scholar.google.com/scholar_lookup?&title=The%20hollow%20fiber%20assay&pages=109-120&publication_year=1999&author=Hollingshead%2CM&author=Plowman%2CJ&author=Alley%2CM&author=Mayo%2CJ&author=Sausville%2CE have?
• How much does https://doi.org/10.1016%2FS0169-409X%2896%2900423-1 pull in monthly?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Experimental%20and%20computational%20approaches%20to%20estimate%20solubility%20and%20permeability%20in%20drug%20discovery%20and%20development%20settings.%20Adv&journal=Drug%20Delivery%20Rev&doi=10.1016%2FS0169-409X%2896%2900423-1&volume=23&pages=3-25&publication_year=1997&author=Lipinski%2CCA&author=Lombardo%2CF&author=Dominy%2CBW&author=Feeney%2CPJ produce monthly?
• What are the total earnings of https://doi.org/10.1093%2Fjnci%2F83.11.757?
• How much cash flow does http://scholar.google.com/scholar_lookup?&title=Feasibility%20of%20a%20high-flux%20anticancer%20drug%20screen%20using%20a%20diverse%20panel%20of%20cultured%20human%20tumor%20cell%20lines&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2F83.11.757&volume=83&pages=757-766&publication_year=1991&author=Monks%2CA&author=Scudiero%2CD&author=Skehan%2CP&author=Shoemaker%2CR&author=Paull%2CK&author=Vistica%2CD&author=Hose%2CC&author=Langley%2CJ&author=Cronise%2CP&author=Vaigro-Wolff%2CA&author=Gray-Goodrich%2CM&author=Campbell%2CH&author=Mayo%2CJ&author=Boyd%2CM have monthly?
• How much income is https://doi.org/10.1093%2Fjnci%2F81.14.1088 earning monthly?
• Earnings of http://scholar.google.com/scholar_lookup?&title=Display%20and%20analysis%20of%20patterns%20of%20differential%20activity%20of%20drugs%20against%20human%20tumor%20cell%20lines%3A%20development%20of%20the%20mean%20graph%20and%20COMPARE%20algorithm&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2F81.14.1088&volume=81&pages=1088-1092&publication_year=1989&author=Paull%2CKD&author=Shoemaker%2CRH&author=Hodes%2CL&author=Monks%2CA&author=Scudiero%2CDA&author=Rubinstein%2CL&author=Plowman%2CJ&author=Boyd%2CMR
• How much profit is http://scholar.google.com/scholar_lookup?&title=Prediction%20of%20biochemical%20mechanism%20of%20action%20from%20the%20in%20vitro%20antitumor%20screen%20of%20the%20National%20Cancer%20Institute&pages=9-45&publication_year=1995&author=Paull%2CKD&author=Hamel%2CE&author=Malspeis%2CL making per month?
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9850044?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Angiogenesis%20in%20the%20hollow%20fiber%20tumor%20model%20influences%20drug%20delivery%20to%20tumor%20cells%3A%20implications%20for%20anticancer%20drug%20screening%20programs&journal=Cancer%20Res&volume=58&pages=5263-5266&publication_year=1998&author=Phillips%2CRM&author=Pearce%2CJ&author=Loadman%2CPM&author=Bibby%2CMC&author=Cooper%2CPA&author=Swaine%2CDJ&author=Double%2CJA bring in?
• What's https://link.springer.com/doi/10.1007/978-1-4615-8152-9_6's gross income?
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=Human%20tumor%20xenograft%20models&doi=10.1007%2F978-1-4615-8152-9_6&pages=101-125&publication_year=1997&author=Plowman%2CJ&author=Dykes%2CDJ&author=Hollingshead%2CM&author=Simpson-Herren%2CL&author=Alley%2CMC?
• Get to know https://doi.org/10.1023%2FA%3A1008333901925's earnings
• How much profit is http://scholar.google.com/scholar_lookup?&title=Evolving%20approaches%20to%20cancer%20drug%20discovery%20and%20development%20at%20the%20National%20Cancer%20Institute%2C%20USA&journal=Annals%20Oncol&doi=10.1023%2FA%3A1008333901925&volume=10&pages=1287-1291&publication_year=1999&author=Sausville%2CEA&author=Feigal%2CE making per month?
• Financial intake of https://doi.org/10.1016%2F0277-5379%2890%2990196-Z
• What's the income of http://scholar.google.com/scholar_lookup?&title=Correlation%20of%20drug%20response%20in%20patients%20and%20in%20the%20clonogenic%20assay%20with%20solid%20human%20tumour%20xenografts&journal=Eur%20J%20Cancer&doi=10.1016%2F0277-5379%2890%2990196-Z&volume=26&pages=901-905&publication_year=1990&author=Scholz%2CCC&author=Berger%2CDP&author=Winterhalter%2CBR&author=Henss%2CH&author=Fiebig%2CHH?
• Earnings of http://scholar.google.com/scholar_lookup?&title=Preclinical%20drug%20development%3A%20rationale%20and%20methods&journal=Seminars%20Oncol&volume=8&pages=349-361&publication_year=1981&author=Venditti%2CJM
• Earnings of https://doi.org/10.1016%2FS1054-3589%2808%2960263-X
• http://scholar.google.com/scholar_lookup?&title=Current%20NCI%20preclinical%20antitumor%20screening%20in%20vivo%3A%20results%20of%20tumor%20panel%20screening%2C%201976%E2%80%931982%2C%20and%20future%20directions&journal=Adv%20Pharmacol%20Chemother&doi=10.1016%2FS1054-3589%2808%2960263-X&volume=20&pages=1-19&publication_year=1984&author=Venditti%2CJM&author=Wesley%2CRA&author=Plowman%2CJ's total income per month
• How much income is http://scholar.google.com/scholar_lookup?&title=The%20chemotherapy%20program%20of%20the%20National%20Cancer%20Institute%3A%20history%2C%20analysis%20and%20plans&journal=Cancer%20Chemother%20Rep&volume=50&pages=349-540&publication_year=1966&author=Zubrod%2CCG&author=Schepartz%2CS&author=Leiter%2CJ&author=Endicott%2CKM&author=Carrese%2CLM&author=Baker%2CCG earning monthly?
• How much does https://citation-needed.springer.com/v2/references/10.1054/bjoc.2001.1796?format=refman&flavour=references bring in each month?
• How much income does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J%20I%20Johnson have?
• How profitable is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J%20I%20Johnson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S%20Decker
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S%20Decker%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en produce monthly?
• Income figures for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=D%20Zaharevitz
• What's the monthly income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22D%20Zaharevitz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=L%20V%20Rubinstein earn?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22L%20V%20Rubinstein%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
• What's the income generated by https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J%20M%20Venditti each month?
• What's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J%20M%20Venditti%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How profitable is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S%20Schepartz?
• How much profit is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S%20Schepartz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en making per month?
• Get to know https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S%20Kalyandrug's earnings
• What is the monthly revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S%20Kalyandrug%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M%20Christian pull in?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M%20Christian%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate monthly?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S%20Arbuck pull in?
• How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S%20Arbuck%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M%20Hollingshead's revenue stream
• Learn about the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M%20Hollingshead%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's the financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=E%20A%20Sausville?
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22E%20A%20Sausville%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's financial summary
• Check the income stats for https://s100.copyright.com/AppDispatchServlet?title=Relationships%20between%20drug%20activity%20in%20NCI%20preclinical%20in%20vitro%20and%20in%20vivo%20models%20and%20early%20clinical%20trials&author=J%20I%20Johnson%20et%20al&contentID=10.1054%2Fbjoc.2001.1796©right=The%20Author%28s%29&publication=0007-0920&publicationDate=2001-05-15&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY-NC-SA
• How much does https://citation-needed.springer.com/v2/references/10.1054/bjoc.2001.1796?format=refman&flavour=citation generate monthly?
• How much does https://doi.org/10.1186/s42826-024-00195-6 generate monthly?
• What's the financial intake of https://doi.org/10.1186/s12885-022-10428-3?
• What are the earnings of https://doi.org/10.1038/s41416-023-02186-1?
• https://doi.org/10.1007/s00262-023-03433-3's financial summary
• How much income does https://doi.org/10.1186/s40545-022-00445-9 have?
• What's the income of https://www.protocols.io/?
• https://www.natureindex.com/'s revenue stream
• http://www.naturechina.com's financial summary
• https://www.natureasia.com/ja-jp's total income per month

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Prism.js
• Zoom.js

Emails and Hosting {✉️}

Mail Servers:

• mxa-002c5801.gslb.pphosted.com
• mxb-002c5801.gslb.pphosted.com

Name Servers:

• pdns1.ultradns.net
• pdns2.ultradns.net
• pdns3.ultradns.org
• pdns4.ultradns.org
• pdns5.ultradns.info
• pdns6.ultradns.co.uk

CDN Services {📦}

• Crossref